Search results
Car T-Cell Therapy
WNDU 16 South Bend· 2 days agoMedical experts call it a ‘breakthrough’ and ‘gamechanger’ when it comes to cancer treatment. “Immunotherapy has really come on as quite an advance in...
Strengthening CAR-T Therapy to Work Against Solid Tumors
WFRV 5 Green Bay· 7 days agoThe promising findings, reported today in Science Advances, involve CAR-T cell therapy, which supercharges the immune ...
Remarkable cancer breakthrough shows woman's brain tumor almost disappear in just five days
UNILAD· 2 days agoMass General Cancer Center researchers worked in collaboration with Mass General neurosurgeons to...
Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
The Record Gazette· 22 hours ago"We continue to build momentum in the clinical development of our lead product candidate, KYV-101, as we seek to bring autoimmune CAR T-cell< ...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 1 day agoThe data compared CAR-T cells derived from Celularity’s proprietary T cell platform with CAR-< ...
Fighting lymphoma: Treatment options include alter | Newswise
Newswise· 2 days agoChemotherapy is usually the first treatment doctors try to treat lymphoma, including the two most common forms: non-Hodgkin and Hodgkin. Lymphoma is a blood cancer that begins when a germ-fighting ...
Kite and Arcellx prepare to launch Phase III multiple myeloma trial
Clinical Trials Arena via Yahoo Finance· 5 days agoAnito-cel is a B-cell maturation antigen chimeric antigen receptor (BCMA CAR ...
Breakthrough therapies are saving lives. Can we afford them?
San Jose Mercury News· 3 days agoLast month, Stanford became the first hospital in the nation to use a new $515,000 cell therapy to...
Cost and Kymriah: Financial assistance options, savings, more
Medical News Today· 5 days agoKymriah (tisagenlecleucel) is a brand-name intravenous (IV) infusion prescribed for certain blood...
Precigen Reports First Quarter 2024 Financial Results and Business Updates
Morningstar· 22 hours ago– Pivotal Phase 2 study data of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis to be presented at the 2024 ASCO Annual Meeting as a late-breaking oral presentation on June 3rd – – Company to host a conference